# Pierre Fabre Medicament clinical trials: 73 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 73 trials with Pierre Fabre Medicament as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pierre Fabre Medicament: 73 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pierre-fabre-medicament

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 73
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 73, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 27, 2025 | NCT07144709 | A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic... | Pierre Fabre Medicament | Observational | Completed | Benign Prostatic Hyperplasia | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144709) |
| July 31, 2025 | NCT07096206 | Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International Study | Pierre Fabre Medicament | Observational | Completed | X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096206) |
| November 15, 2024 | NCT06690489 | An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast... | Pierre Fabre Medicament | Observational | Completed | Early Breast Cancer, Skin Condition, Quality of Life | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690489) |
| November 14, 2024 | NCT06688370 | The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study | Pierre Fabre Medicament | Observational | Terminated | Sore-throat, Cough | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06688370) |
| November 1, 2024 | NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | Pierre Fabre Medicament | Phase 1/2 | Recruiting | Solid Tumor, MET Alteration | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06669117) |
| October 2, 2024 | NCT06623773 | Study on Structum® in Adult Patients With Osteoarthritis (TRUST) | Pierre Fabre Medicament | Observational | Completed | Osteoarthritis, Knee | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06623773) |
| August 22, 2024 | NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs | Pierre Fabre Medicament | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06567015) |
| July 15, 2024 | NCT06500494 | To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment | Pierre Fabre Medicament | Observational | Active not recruiting | Advanced Breast Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06500494) |
| September 21, 2023 | NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or... | Pierre Fabre Medicament | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043817) |
| April 12, 2023 | NCT05810740 | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | Pierre Fabre Medicament | Phase 1 | Completed | Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05810740) |
| October 31, 2022 | NCT05599334 | A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib | Pierre Fabre Medicament | Observational | Completed | Breast Cancer, Adjuvant Therapy, HER2-positive Breast Cancer | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05599334) |
| September 21, 2022 | NCT05546905 | A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) | Pierre Fabre Medicament | Observational | Completed | Metastatic Non-small Cell Lung Cancer, BRAF V600 Mutation | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05546905) |
| September 19, 2022 | NCT05545215 | Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema | Pierre Fabre Medicament | Observational | Withdrawn | Chronic Hand Eczema | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05545215) |
| August 8, 2022 | NCT05491057 | Treatment Patterns of Neratinib in HER2+ EBC in China | Pierre Fabre Medicament | Observational | Unknown | Breast Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05491057) |
| March 8, 2022 | NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | Pierre Fabre Medicament | Phase 3 | Active not recruiting | Melanoma | 815 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05270044) |
| January 19, 2022 | NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic... | Pierre Fabre Medicament | Phase 2 | Active not recruiting | Non-Small Cell Lung Cancer | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05195632) |
| November 2, 2021 | NCT05103891 | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | Pierre Fabre Medicament | Phase 1 | Unknown | Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103891) |
| August 13, 2021 | NCT05004350 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic... | Pierre Fabre Medicament | Phase 2 | Completed | BRAF V600E, Metastatic Colorectal Cancer | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05004350) |
| August 12, 2021 | NCT05003622 | Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | Pierre Fabre Medicament | Phase 1 | Completed | BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05003622) |
| June 4, 2021 | NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Pierre Fabre Medicament | Phase 1 | Recruiting | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04913285) |
| June 3, 2021 | NCT04911998 | A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients | Pierre Fabre Medicament | Observational | Completed | Melanoma (Skin), Metastatic Melanoma, BRAF V600 Mutation | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04911998) |
| May 6, 2021 | NCT04875026 | Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised... | Pierre Fabre Medicament | Phase 4 | Completed | Actinic Keratoses | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04875026) |
| February 18, 2021 | NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Pierre Fabre Medicament | Phase 1 | Withdrawn | BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04759846) |
| September 25, 2020 | NCT04564417 | First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic... | Pierre Fabre Medicament | Phase 1 | Terminated | Locally Advanced or Metastatic Solid Tumors | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04564417) |
| September 18, 2020 | NCT04554914 | A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Pierre Fabre Medicament | Phase 2 | Active not recruiting | Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04554914) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 5 |
| Phase 2 | 17 |
| Phase 3 | 17 |
| Phase 4 | 4 |
| Not applicable | 3 |
| Observational | 12 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 53 |
| Recruiting | 5 |
| Terminated | 5 |
| Active not recruiting | 4 |
| Withdrawn | 4 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 7 |
| Melanoma | 7 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Smoking Cessation | 5 |
| Tobacco Use Disorder | 5 |
| Neoplasm Metastasis | 4 |
| Fibromyalgia | 3 |
| Colorectal Neoplasms | 3 |
| Prostatic Hyperplasia | 3 |
| Respiratory Tract Infections | 3 |
| Dermatitis, Atopic | 2 |
| Dermatitis | 2 |
| Eczema | 2 |
| Lung Neoplasms | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Pharyngitis | 2 |
| Osteoarthritis, Knee | 2 |
| Anemia, Iron-Deficiency | 2 |
| Carcinoma, Transitional Cell | 2 |
| Urinary Bladder Neoplasms | 2 |
| Lymphoproliferative Disorders | 2 |
| Epstein-Barr Virus Infections | 2 |
| Diabetic Neuropathies | 1 |
| Diabetes Mellitus | 1 |
| Diabetic Foot | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Collection agencies in the United States](https://specstream.ai/data/businesses/collection-agencies/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [Shipping collection companies in the United States](https://specstream.ai/data/businesses/shipping-collection-companies/united-states)
- [Behavior analysis services in the United States](https://specstream.ai/data/businesses/behavior-analysis-services/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
